Weeks after an injection of stem cells delivered to the brain, 80% of patients had improved CSF biomarkers with no adverse effects.

The stock's fall snapped a four-day winning streak.

Learn more about whether Axon Enterprise, Inc. or Leonardo DRS, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Leidos Holdings, Inc. LDOS is scheduled to release first-quarter 2025 results on May 6, before market open. The company ...

AXON's first-quarter 2025 results are likely to gain from the strong demand for TASER devices and higher cartridge revenues.

Flex Ltd. FLEX is scheduled to report fourth-quarter fiscal 2025 results on May 7, before the market opens. The Zacks ...